A Phase 2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.

开始日期2026-03-21

申办/合作机构

National Cancer Institute

NCT07003295

/ Not yet recruiting临床2期IIT

A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated With CD19-Directed CAR T-Cell Therapy

This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory) after receiving CD19-directed chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy is a form of immunotherapy where the immune system cell, T-cell, is changed to attack cancer cells. Glofitamab is a bispecific antibody that can bind to two different antigens at the same time. Glofitamab binds to CD3, a protein found on T cells (a type of white blood cell), and CD20 a protein found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving glofitamab and obinutuzumab may be safe, tolerable, and/or effective in treating patients with relapsed or refractory mantle cell lymphoma after receiving CD19-directed CAR T-cell therapy.

开始日期2025-10-31

申办/合作机构

National Cancer Institute

NCT06967610

/ Not yet recruiting临床2期IIT

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.

开始日期2025-10-30

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

100 项与奥妥珠单抗相关的临床结果

登录后查看更多信息

100 项与奥妥珠单抗相关的转化医学

登录后查看更多信息

100 项与奥妥珠单抗相关的专利（医药）

登录后查看更多信息

1,146

项与奥妥珠单抗相关的文献（医药）

2025-09-09·Blood Advances

A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma

Article

作者: Wang, Michael ; Fowler, Nathan H. ; Neelapu, Sattva S. ; Henderson, Jared ; Akkad, Neha ; Flowers, Christopher R. ; Fayad, Luis ; Chihara, Dai ; Green, Michael ; Ahmed, Sairah ; Nastoupil, Loretta J. ; Lee, Hun Ju ; Ibanez, Karina ; Hagemeister, Fredrick B. ; Nair, Ranjit ; Feng, Lei ; Strati, Paolo ; Rodriguez, Maria Alma ; Davis, R. Eric ; Westin, Jason R. ; Claret, Linda

Abstract:

Follicular lymphoma (FL) has a clinical course that is often characterized by high response rates to first-line therapy, followed by multiple relapses over a prolonged natural history. Currently, there are multiple possible approaches to frontline therapy for untreated advanced-stage FL, but there is an ongoing debate around what is the preferred approach. Based on the benefits seen with combining lenalidomide, an immunomodulatory agent, with rituximab, an anti-CD20 antibody, we aimed to evaluate the safety and efficacy of lenalidomide in combination with obinuzutumab, an anti-CD20 antibody with enhanced antibody-dependent cellular cytotoxicity. The eligibility criteria included a diagnosis of FL, grade 1 to 3a, stage II to IV, Eastern Cooperative Oncology Group performance status ≤ 2, adequate organ function, and high tumor burden according to the Groupe d’Étude des Lymphomes Folliculaires criteria. Participants received 6 cycles of induction with the combination, followed by 24 cycles of maintenance. Among 90 patients, the primary end point, 2-year progression-free survival (PFS), was 93.3% (95% confidence interval [CI], 88.2-98.6), and the median PFS was not reached with a median follow-up of 70.7 months. The complete response rate at 30 months was 89.7% (95% CI, 81.3-95.2). The most common adverse events (AEs) of any grade were diarrhea (61.1%), maculopapular rash (53.3%), and fatigue (52.2%). The most common AEs ≥ grade 3 were neutropenia (18.9%), maculopapular rash (11.1%), and pneumonia (6.7%). In this single-center trial, these findings indicate that, for patients with previously untreated, high tumor burden FL, obinutuzumab and lenalidomide led to robust and durable responses with a favorable 2-year PFS and manageable safety profile. This trial was registered at www.clinicaltrials.gov as #NCT02871219.

2025-08-18·BRITISH JOURNAL OF DERMATOLOGY

Successful treatment of pemphigus vulgaris with obinutuzumab

Article

作者: Ostlund, Lauren ; Tang-Whitmore, Colin ; Munson, Kati ; Schultz, Brittney

This letter highlights the successful use of obinutuzumab as an alternative therapy for a patient with pemphigus vulgaris who could not tolerate rituximab. Our findings suggest that obinutuzumab may offer a promising treatment option for patients with autoimmune skin diseases when first-line therapies fail.

2025-08-15·Blood Research

Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors.

Article

作者: Yoon, Sang Eun ; Choi, Yunsuk ; Park, Hyunkyung ; Kim, Seok Jin ; Park, Han-Seung ; Lee, Jung-Hee ; Hur, Joon Young ; Won, Young-Woong ; Choi, Jung Hye ; Lee, Je-Hwan ; Kim, Won Seog

PURPOSE:

Bruton tyrosine kinase inhibitors (BTKis) are effective and well-tolerated treatments for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Here, we describe the clinical characteristics of hepatitis B virus (HBV) reactivation in patients with hematological malignancies treated with BTKis.

METHODS:

Patients were required to have a pathologically confirmed diagnosis of CLL or MCL, receive at least one cycle of ibrutinib or zanubrutinib, and have either positive hepatitis B surface antigen or hepatitis B core antibody at diagnosis. Patients were excluded if they had received rituximab or obinutuzumab within the previous 12 months.

RESULTS:

We identified five patients with CLL and one with MCL who had resolved HBV infections and received BTKis during the study period. None of the patients received anti-HBV prophylaxis after CLL diagnosis. The patient with MCL who received zanubrutinib was confirmed to have HBV reactivation even after prophylactic entecavir administration followed by tenofovir. All five patients with CLL received ibrutinib as second-line therapy. A 62-year-old man died of hepatorenal syndrome associated with HBV reactivation despite entecavir treatment.

CONCLUSION:

To the best of our knowledge, this is the first description of HBV-related death in patients receiving BTKis from HBV-endemic areas, and the first case of HBV reactivation associated with zanubrutinib despite previous entecavir prophylaxis. Further prospective studies are warranted to develop useful guidelines for monitoring HBV DNA and antiviral prophylaxis to prevent HBV reactivation after BTKi therapy.

511

项与奥妥珠单抗相关的新闻（医药）

2025-09-04

·学术经纬

从宣判“死刑”到有望治愈，这位诺奖得主用一生改写白血病患者命运

编者按：20世纪中叶，科学界对白血病几乎没有有效的控制策略。由于当时的治疗手段非常有限，患者在诊断后不久便不幸去世，白血病的诊断往往代表着“死刑”。从20世纪的同种异体骨髓移植手术到本世纪不断涌现的靶向疗法，科学界的持续探索为白血病患者打开了通往治愈的大门。长期以来，药明康德也在支持全球合作伙伴从药物研究（R）、开发（D）到商业化生产（M）各个阶段的需求，通过独特的一体化、端到端CRDMO模式，助力多款白血病新疗法问世，造福全球患者。值此世界白血病日，本文将回顾由科学铺设的白血病治疗之路。 “骨髓移植之父”的拯救之路白血病由骨髓产生过多异常白细胞而引发，并且会抑制正常细胞的发育，导致红细胞无法将氧气输送到全身。那时，科学界曾出现了一些较为“超前”的想法：用骨髓移植来帮助产生全新的健康血细胞。不过在当时，动物模型的表现普遍不太理想，接受移植的受体会排斥移植的骨髓，并且这些骨髓难以长时间存活进而发挥治疗效果。一些声音认为，这条路注定走不通，相关研究也一度进展缓慢。 20世纪30年代，在美国得克萨斯大学读书的Donnall Thomas正在为生活费所奔波。为了能维持学业和日常开销，Donnall做了许多兼职工作，包括在宿舍的前台进行接待。此时的他还不知道自己将在未来改变白血病治疗领域格局，更不用说“骨髓移植之父”的称号以及诺贝尔奖。 ▲Donnall Thomas因“在器官或细胞移植方面治疗疾病作出的贡献”获得了1990年的诺贝尔生理学或医学奖（图片来源：参考资料[1]，Nobel Foundation archive）在后来的自传中，他特别提到了与妻子相遇的那个日子——那天，得克萨斯州罕见地下了雪。Donnall在刚准备进入宿舍时，被一个雪球砸中了脸，他循着雪球方向找到了一名女生。就这样，他认识了Dottie Martin。在之后的生涯中，Dottie不仅是妻子，更是成为了Donnall的得力助手。当Donnall毕业进入哈佛医学院，Dottie就辞去了自己的新闻业工作，并毅然加入医学院参加了实验室技术员培训，之后夫妻两人一直一起开展研究工作。 Donnall于1946年在哈佛完成住院医生训练，此后先后进入西雅图和波士顿的多家医院工作。他亲眼见证了许多白血病患者与家属在病痛面前的绝望。这些经历使他逐渐意识到，传统手段几乎无法为这类病人带来真正希望。他联想到，有研究者发现保护脾脏可以让小鼠免受致命辐射的伤害，通过骨髓输注也可以获得类似的保护效果。这些结果实际都指向了一个方向，那就是活骨髓细胞具有保护辐射、重构造血系统的作用。于是，Donnall有了一个大胆的假设：能否通过移植健康的骨髓来替代患者病变的造血系统？他建立了一个小型实验室，利用动物模型进行了骨髓移植实验。Dottie负责做放疗、护理和观察，并仔细记录数据。这些实验让他们掌握了骨髓移植的关键技巧。随后，Donnall找到了数名病情危重的白血病患者，他们几乎已经没有其他治疗选择。患者在接受放疗清除原本的造血系统后，接受了近亲的骨髓移植。这是医学史上的首次尝试，也代表着白血病治疗的一个全新里程碑。1957年，Donnall将这些结果发表在《新英格兰医学杂志》上后，立即引起了全球医学界的高度关注。不过，其他学者仍花费了十多年才逐渐接受和认可了这一技术的价值。从“死刑”宣判到治愈希望在这一过程中，Donnall并没有因外界的质疑而停下脚步。他加入了弗雷德·哈钦森癌症研究中心（Fred Hutchinson Cancer Research Center），成为该中心的创始成员之一。在骨髓移植早期，最棘手的问题就是免疫排斥。而随着人类白细胞抗原（HLA）系统的发现与应用，科学家逐渐认识到，如果供者和受者的 HLA 类型差异过大，移植就几乎必然失败；反之，如果供受双方的 HLA 高度相似甚至完全匹配，移植的成功率就会显著提高。 Donnall在后续的骨髓移植试验中，提前进行了HLA配型筛选。他还研究了另一种抗免疫排斥药物甲氨蝶呤，成功降低了“移植物抗宿主反应”发生率。此外，Donnall还发现当白血病患者接受同卵双胞胎的移植后，他们的病情往往在移植后短短几个月内复发。但是，接受与自身略有不同的细胞（例如来自基因不完全匹配的兄弟姐妹，甚至是无血缘关系的捐赠者）的患者，复发率要低得多。这些发现为后续的骨髓移植的成功发展和普及奠定了重要基础。在上世纪70年代末，骨髓移植刚刚出现在公众视野中的时候，全球每年仅仅只有数百例移植手术。仅过了不到10年，这一数字就增长了约10倍。在过去，白血病的诊断意味着很快就会去世。而随着骨髓移植的普及，部分白血病类型，例如儿童急性淋巴细胞性白血病（ALL）的五年生存率可提升至90%。 1990年10月的一个凌晨，一道电话铃声将Donnall从睡梦中吵醒。他接起电话——是一名记者想向他采访获得诺贝尔奖的感受。他还以为是哪位同事的恶作剧，半信半疑的Dottie也让他赶紧应付两句，挂掉电话继续睡觉。但随后，电话开始响个不停，更多的记者打了过来，他这才相信自己获得了当年的诺贝尔生理学或医学奖。待颁奖典礼时，Donnall与Dottie一同前往了瑞典斯德哥尔摩。在演讲中，Donnall看向Dottie，“如果没有Dottie，我可能做不到这一切。” 图片来源：123RF 获奖后，Donnall将奖金全部捐赠给了弗雷德·哈钦森癌症研究中心，助力更多后续研究的开展。这里的研究者仍在继续探索更多拯救白血病的治疗策略，例如后续发展的血液干细胞移植已用于治疗多种白血病和淋巴瘤，扩大移植受益群体的范围；减轻强度的移植术，使身体较弱的患者也能接受移植。另外，研究者通过能够精确识别肿瘤的免疫分子，或改造出的能够直接靶向并摧毁癌细胞的杀伤性T细胞来清除肿瘤。基于数十年在白血病领域分子机制的探索，研究团队还在积极与其他团队合作，研究耐药机制和与免疫疗法结合的策略，寻找可用的小分子抑制剂。这也推动了更多救命策略的诞生。新疗法改写白血病治疗格局在Donnall等人前期工作成果的基础上，近年来多种白血病疗法陆续涌现，已经挽救了大量患者的生命。以一种常见的白血病亚型——慢性淋巴细胞白血病（CLL）为例，造血干细胞移植为患者提供了治愈的手段，而对于因为身体状况、缺乏合适供者而无法接受移植的CLL患者，近年来多款不同类型的获批药物为他们实现了疾病的控制。进入21世纪以来，美国FDA已经批准了至少14款治疗CLL的新疗法，一个重要转变是靶向疗法的兴起。例如，布鲁顿氏酪氨酸激酶（BTK）在CLL的癌细胞中表达升高，成为CLL治疗的重要靶点。BTK抑制剂伊布替尼（ibrutinib）在2013年获批用于套细胞淋巴瘤治疗后，又在2014年获批用于CLL的治疗。后续随访结果显示，伊布替尼治疗CLL的总缓解率达到88%。此外，已获FDA批准的BTK抑制剂还包括泽布替尼（zanubrutinib）、首个非共价BTK抑制剂匹妥布替尼（pirtobrutinib）、阿可替尼（acalabrutinib）。图片来源：123RF PI3K是另一种在B细胞恶性肿瘤中过度表达的蛋白，PI3K-δ抑制剂艾代拉利司（idelalisib）和PI3K-δ、PI3K-γ双重抑制剂度恩西布（duvelisib）相继获批，用于治疗复发/难治性CLL。维奈克拉（venetoclax）则是一种BCL-2抑制剂，通过选择性抑制B细胞淋巴瘤因子-2（BCL-2）的功能，促进癌细胞凋亡。以CD20等抗原为靶点的单克隆抗体，是CLL靶向治疗的另一个重要方向。于20世纪末问世的利妥昔单抗（rituximab）是一款靶向CD20的单抗，其新适应症在2010年获FDA批准，与其他药物联合使用，治疗CD20阳性CLL患者。此外，已经获批用于治疗CLL的CD20单抗还包括奥法妥木单抗（ofatumumab）、奥妥珠单抗（obinutuzumab）；阿仑珠单抗（alemtuzumab）则是一款靶向CD52的单抗药物。除上述药物之外，近年来获批的CLL疗法还有化疗药物苯达莫司汀（bendamustine），以及2024年获批的靶向CD19的CAR-T细胞疗法lisocabtagene maraleucel（liso-cel）。药明康德很高兴能为其中多款疗法提供赋能、助力合作伙伴的这些创新疗法来到全球患者身边。这些获批药物在很大程度上改善了CLL患者的生活质量、延长了患者寿命，但科学与产业界的创新脚步仍未停下。当下还有近200款针对CLL的新疗法正处于积极的临床研究中，有望在未来造福更多患者。其中，多款药物已进入3期临床阶段，涵盖小分子靶向药和靶向蛋白降解剂等多种类型。作为全球医药创新的赋能者，长期以来，药明康德都在支持全球合作伙伴从药物研究（R）、开发（D）到商业化生产（M）各个阶段的需求，通过独特的一体化、端到端CRDMO模式，助力突破性疗法研发。药明康德也将与业界同仁携手同行，共同推动白血病治疗的未来发展。参考资料： [1] E. Donnall Thomas, Biographical. Retrieved September 2, 2025 from https://www.nobelprize.org/prizes/medicine/1990/thomas/biographical/ [2] Remembering E. Donnall Thomas. Retrieved September 2, 2025 from https://www.fredhutch.org/en/news/center-news/2012/10/e-donnall-thomas-obituary.html [3] A pioneering procedure’s expanding influence. Retrieved September 2, 2025 from https://www.fredhutch.org/en/news/center-news/2015/08/bone-marrow-transplant-influence.html [4] E. Donnall Thomas. Retrieved September 2, 2025 from https://www.washington.edu/alumni/columns/march98/thomas.html 欢迎转发到朋友圈，谢绝转载到其他平台。如有开设白名单需求，请在“学术经纬”公众号主页回复“转载”获取转载须知。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。更多推荐点个“在看”再走吧~

2025-09-03

·ETPharma

GST waiver for 36 drugs; formulations under 5% slab

New Delhi: Executing the much-awaited overhaul of the Goods and Services Tax (GST) regime, the GST Council has brought a major relief for patients by reducing the indirect tax on medicines to 5 per cent, along with exempting as many as 36 life-saving medicines and other critical drugs. The GST council—a statutory body highest decision making body on indirect taxes led by the Union Finance Ministry at its 56th meeting in the national capital has recommended to reduce the GST on all drugs and medicines (finished formulations) from 12 per cent to 5 per cent under the new two-tier tax structure of 5 and 18 per cent slabs to be effective from September 22. Additionally the body has also recommended to exempt GST on 33 lifesaving drugs and on 3 other medicines used for treatment of cancer, rare diseases and other severe chronic diseases. Speaking at a press briefing after the council 10.5-hour long marathon meet, Finance Minister Nirmala Sitharaman said, “all recommendations have been cleared with zero reservations and have corrected various inverted duty structure problems, classification related issues and that this rationalization exercise will bring predictability and stability of GST.” “These reforms have been carried out with a focus on the common man, and after a rigorous evaluation process in most sectors including healthcare, the rates have come down drastically, she added. Previously, medicines in India were taxed at 5 per cent for life-saving and essential drugs, and at 12 per cent for others but following the announcement all medicines will attract a standard duty of 5 per cent with extensions for several medicines specified at the end of this article. Welcoming the move, Sudarshan Jain, Secretary General, IPA said, “the decision to exempt life-saving and cancer medicines from GST, is a step that will bring direct relief to patients and their families. and, the reduction in GST on a wide range of medicines from 12 per cent to 5 per cent will further help to ease the overall treatment burden and make essential therapies more affordable.” Meanwhile, for companies, the clarity on a 5 per cent slab and exemptions removes long-standing ambiguity, enabling transparent pricing and better market planning. The move will expand access in semi-urban and rural markets, ease litigation, and free up resources for innovation, said Manoj Mishra, Partner and Tax Controversy Management Leader, Grant Thornton Bharat LLP. Notably, on the issue of inverted duty involving APIs and key starting materials—which are currently taxed at 18 per cent against 12 or 5 per cent for finished formulations—further clarity is awaited from the industry. ETPharma earlier reported that, in a letter to the Finance Minister, the national chemist body, the All India Organisation of Chemists and Druggists (AIOCD) had urged, “to bring all medicines including vitamins, probiotics, nutritional, food supplements under the 5 per cent GST slab. The rate rationalization comes days after Prime Minister Narendra Modi had pitched for introducing next-gen reforms across sectors to “increase ease of living for the common man and strengthen the economy.” However, this rationalization brings a revenue shortfall challenge for governments with states likely to bear a greater share of the burden, as they receive over 40 percent of the inter-state inflows in addition to their own SGST collections. Responding to a media query at the media briefing Arvind Shrivastava, Revenue Secretary said that, based on the consumption of FY23-24 the ministry has estimated that the net revenue implication of this proposal will be around Rs 48,000 crore. “However the exercise will trigger buoyancy effects and will have a positive impact on consumer and compliance. And therefore we believe this proposal will be fiscally sustainable both for centers and the states,” Shrivastava noted. ' S.no. Drug Indication Brand name and (Company) 1 Onasemnogene abeparvovec SMA (One-time gene therapy) Zolgensma (Novartis) 2 Asciminib Blood Cancer Scemblix (Novartis) 3 Mepolizumab Asthma Nucala (GSK) 4 Pegylated Liposomal Irinotecan Pancreatic Cancer Onivyde (Ipsen) 5 Daratumumab Cancer Darzalex (J&J subsidiary) 6 Daratumumab subcutaneous Cancer Darzalex Faspro (J&J subsidiary) 7 Teclistamab Blood Cancer Tecvayli (J&J subsidiary) 8 Amivantamab Lung Cancer Rybrevant (J&J subsidiary) 9 Alectinib Lung Cancer Alecensa (Roche) 10 Risdiplam SMA Evrysdi (Roche) 11 Obinutuzumab Blood Cancer Gazyva (Roche) 12 Polatuzumab vedotin Blood Cancer Polivy (Roche) 13 Entrectinib Cancer Rozlytrek (Roche) 14 Atezolizumab Cancer (PD-L1 immunotherapy) Tecentriq (Roche) 15 Spesolimab GPP flares Spevigo (Boehringer Ingelheim) 16 Velaglucerase Alpha Gaucher Vpriv (Takeda) 17 Agalsidase Alfa Fabry disease Replagal (Takeda) 18 Rurioctocog Alpha Pegol Hemophilia Adynovate (Takeda) 19 Idursulphatase Type II Mucopolysaccharidosis Elaprase (Takeda) 20 Alglucosidase Alfa Pompe Myozyme (Sanofi) 21 Laronidase Type I Mucopolysaccharidosis Aldurazyme (Sanofi) 22 Olipudase Alfa ASMD Xenpozyme (Sanofi) 23 Tepotinib Lung Cancer Tepmetko (Maerck KGaA) 24 Avelumab Cancer (PDL-1 immunotherapy) Bavencio (Pfizer) 25 Emicizumab Hemophilia Hemlibra (Roche subsidiary) 26 Belumosudil cGVHD - 27 Miglustat Gaucher Zavesca (J&J subsidiary) 28 Velmanase Alfa Alpha-mannosidosis - 29 Alirocumab Cholesterol lowering drug (LDL-C) Praluent (Sanofi) 30 Evolocumab Cholesterol lowering drug (LDL-C) Repatha (Amgen) 31 Cystamine Bitartrate Cystagon - 32 CI-Inhibitor injection Hereditary Angioedema - 33 Inclisiran Cholesterol lowering drug (LDL-C) Leqvio (Novartis) 34 Agalsidase Beta Fabry disease Fabrazyme (Sanofi) 35 Imiglucerase Gaucher Cerezyme (Sanofi) 36 Eptacog alfa activated recombinant coagulation factor VIIa Hemophilia NovoSeven Note: Above is the list of medicines exempted from GST tax recommended by the 56th GST Council Meet/ Source: PIB By Abhijeet Singh ,

基因疗法

2025-08-30

·药明康德

致敬时代 | 近90%患者癌细胞减少或几乎“全消失”！无需再依赖化疗，多款新型抗癌药为这类患者点亮希望

编者按：2025年，药明康德迎来创立25周年的重要里程碑。值此契机，我们向所有与我们共同书写产业变革篇章的科学家、医药人和投资者致以衷心感谢与诚挚敬意，也特别推出“致敬时代”系列，回顾全球同仁如何借助科学与合作的力量，不断拓展治疗边界、改善患者命运。四分之一个世纪的坚守，只为加速每一款新药的诞生。下一个25年，我们将继续心怀感恩与敬畏，依托独特的CRDMO模式，与全球伙伴携手同行，共赴健康未来。白血病是威胁人类生命的常见恶性血液肿瘤之一。但有一种白血病偶尔被人们称为“最轻的白血病”，那就是慢性淋巴细胞白血病（简称慢淋，CLL）。这是一种成熟B淋巴细胞克隆增殖性肿瘤，表现为外周血淋巴细胞增多。慢淋常见于中老年患者，大致可分为两类，有一种生长非常缓慢，患者往往无明显症状，在很长一段时间里不需药物治疗，只需定期找医生随诊；另一种则生长更快、也更严重。尤其是出现耐药和复发的患者，将面临更差的预后。在欧美国家，慢淋是最常见的白血病类型，大约占白血病总体患者的25%～30%。虽然慢淋在亚洲人群里发生率相对较低，但检出率及诊断率也在逐步上升。到目前为止，慢淋唯一可根治的手段就是异基因造血干细胞移植，但不幸的是，很多患者因为年龄、身体状况、供者等各方面原因，没机会接受这样的治疗。因此对大多数慢淋患者来说，治疗的目标是带病生存，能够长期维持在一个比较好的生活状态。图片来源：123RF 直到20世纪中叶，各类白血病依然缺乏有效的治疗手段。20世纪40年代，科学家们发现氮芥对慢性白血病等血液肿瘤有积极作用，白血病自此进入化疗时代。50~70年代，苯丁酸氮芥和环磷酰胺等烷化剂类药物的研发，让慢淋患者获得了30%~40%的缓解率。80~90年代，氟达拉滨等嘌呤类似物成为慢淋的主要治疗手段，让缓解率提升至50%左右。但化疗带来的细胞毒性等问题，依然影响着患者的生活质量。进入21世纪后，慢淋治疗有了非常大的突破，从传统的化疗走向了以靶向治疗为主的时代，还有层出不穷的新型治疗方案正改变着慢淋治疗的版图。作为全球医药及生命科学行业值得信赖的合作伙伴和重要贡献者，药明康德在25年发展历程中，很荣幸见证了多款慢淋新疗法从实验室到临床的突破历程，更通过提供一体化、端到端的新药研发和生产服务，助力全球合作伙伴加速多款慢淋创新疗法的研发进程，造福病患。今天这篇文章将再次回望近25年来慢淋新疗法的攻坚历程，向那些以勇气、坚持与热爱迎难而上的人们致敬。单克隆抗体疗法：开启靶向时代世纪之交，单克隆抗体疗法率先打破了慢淋治疗主要依赖化疗的局面。其中一个重要靶点是CD20。这是一种B细胞分化抗原，在95%以上的B细胞性淋巴瘤中表达，而在造血干细胞、血浆细胞和其他正常组织中不表达。 1997年，基因泰克（现为罗氏旗下子公司）与渤健共同开发的靶向CD20的利妥昔单抗（rituximab，商品名：Rituxan）问世，随后在各类癌症治疗领域都发挥了重要作用，也包括慢淋。科学家发现，利妥昔单抗与氟达拉滨等化疗药物联用比先后单独使用两款药物效果更好。2010年，利妥昔单抗的新适应症获FDA批准，与氟达拉滨和环磷酰胺联合用于治疗初治和既往经治的CD20阳性慢淋患者。利妥昔单抗的成功，也启发产业不断迭代以CD20为目标的单抗药物，例如由Genmab公司与诺华联合开发的第二代CD20单抗代表药物奥法妥木单抗（ofatumumab）。它是一款全人源化单抗，其结合的表位也与利妥昔单抗不同，主要用于对其它治疗或其它单抗不再有应答的患者。2009年，奥法妥木单抗获FDA批准（商品名：Arzerra），用于对氟达拉滨和阿仑珠单抗耐药的慢淋患者。如今，这两款药物均已成为慢淋的主要治疗药物。由GlycArt Biotechnology、罗氏旗下基因泰克与渤健共同开发、2013年获FDA批准用于慢淋的奥妥珠单抗（obinutuzumab，商品名：Gazyva）属于第三代CD20抗体。与前两款药物相比，它杀死慢淋细胞更直接、作用更强，并且早期试验已证实了该药可快速将B细胞从外周血细胞中清除出去。它可与化疗药物或靶向药物伊布替尼一起作为慢淋初治疗法，也可单独治疗复发或对其它治疗无应答的慢淋。除了上述几种单抗，还有针对CD52抗原的单抗药物阿仑珠单抗（alemtuzumab，商品名：Lemtrada）。它由拜耳与赛诺菲共同开发，2001年获美国FDA批准用于治疗对烷化剂和氟达拉滨耐药的进展期慢淋。 BTK抑制剂：伊布替尼惊艳问世，同类靶向药多点开花说到近十多年慢淋靶向疗法的发展，就不得不提到布鲁顿氏酪氨酸激酶（BTK）抑制剂。其中一款重磅新药战绩尤其辉煌，让慢淋化疗成为了历史——它，就是伊布替尼（ibrutinib），一度被称为“慢淋领域的格列卫”。这款新药背后，有着跌宕起伏的研发历程。 20世纪90年代，一种后来被命名为BTK的酪氨酸激酶进入了科学家的视野。BTK被发现在B细胞受体（BCR）信号通路中起着关键作用；而在慢淋的癌细胞里，BTK蛋白水平会出现异常升高。 BTK自然成为了B细胞恶性肿瘤中富有吸引力的一个治疗靶点，很多公司开始针对BTK设计具有激酶选择性的抑制剂，其中也包括Celera Genomics公司。 21世纪初，Celera公司在探索中孕育了一款靶向BTK并与之共价结合的小分子。由于共价药物可与人体内蛋白非选择性、不可逆、永久结合，一旦脱靶结合到正常的人体蛋白上，可能引起严重的毒副作用，这种潜在风险使共价药物一度成为药物研发的禁忌。因此，Celera公司最初并没有把它作为候选药物，而只是当作“工具化合物”协助BTK抑制剂的筛选。 2006年，一家名为Pharmacyclics的公司收购了这款在Celera公司没能得到充分重视的小分子。Pharmacyclics当时的首席执行官、血液肿瘤专家理查德·米勒（Richard Miller）博士敏锐地意识到了它在B细胞癌症中的潜力。尽管他和团队在B细胞淋巴瘤动物模型中证实了这款药物的活性，但很多研发人员对这款共价结合机制的药物仍然持犹疑态度。然而，很多患者正在死亡的边缘。米勒博士不愿意因为对“共价机制”的风险担忧，而让这些患者无止境地等下去。 2009年，这款小分子的1期临床试验启动了。2011年，Pharmacyclics公司报告了它在1b/2期试验中用于一系列B细胞恶性肿瘤的积极数据，不久后，强生旗下杨森制药（现更名为强生创新制药）也宣布与Pharmacyclics进行合作，共同研发这款新药。 2013年11月，以“伊布替尼”之名，这款不负众望的新药获FDA加速批准上市（商品名：Imbruvica）用于套细胞淋巴瘤的治疗。同一时期，它在慢淋中也表现出惊人的疗效，并在2014年2月获得FDA批准用于既往至少接受过一种治疗的慢淋患者。后续发表于2015年的3年随访结果显示，伊布替尼单药治疗就让90%的慢淋既往经治患者和84%的初治患者获得缓解，达到完全缓解的患者分别占7%和23%，总缓解率为88%。也就是说，近90%的患者肿瘤细胞数明显下降或几乎“全消失”。这是一个激动人心的结果，意味着患者可以摆脱对化疗的依赖。图片来源：123RF 更长期的8年随访研究表明，在经治和初治的慢淋患者中，伊布替尼的总缓解率分别高达89%和87%，分别有10%和35%的患者获得完全缓解，中位无进展生存期分别长达52个月和尚未达到，7年总生存率分别达到55%和84%。 2015年，艾伯维以高达210亿美元的金额收购了拥有伊布替尼的Pharmacyclics，与强生共同继续伊布替尼的研究工作。2016年3月，FDA批准了伊布替尼的第5个适应症，单药用于慢淋患者的一线治疗。这是FDA批准的首个“无化疗”慢淋一线治疗方案，意味着伊布替尼可替代化疗作为慢淋的一线治疗选择，是一个重要的里程碑。在推动此次获批的3期临床试验中，与化疗组相比，接受伊布替尼单药治疗的初治慢淋患者总缓解率达到82.4%，是前者（35.3%）的2倍多，无进展生存期显著延长，疾病进展或死亡风险降低84%。如今，伊布替尼已获FDA批准治疗10余项适应症，并成为多种血液肿瘤的一线治疗选择。目前伊布替尼已在全球100多个国家和地区获批，惠及全球超30万患者。此后，更多BTK靶向药物接连问世，让包括慢淋在内的B细胞恶性肿瘤患者的生活迎来了巨大改善。已获FDA批准的BTK抑制剂还包括由百济神州研发的泽布替尼（zanubrutinib），由礼来、Redx Pharma与LOXO Oncology共同开发、可破解共价BTK抑制剂耐药困局的首个非共价（可逆）BTK抑制剂匹妥布替尼（pirtobrutinib），以及由阿斯利康与Acerta Pharma共同开发的阿可替尼（acalabrutinib）。在中国获批用于慢淋的BTK抑制剂还有由诺诚健华与渤健共同研发的奥布替尼。其它靶向抑制剂：瞄准更多靶点随着医药科技的进步，还有更多重要靶点被发现、更多新的重磅药物诞生。与BTK类似，PI3K蛋白在多种B细胞恶性肿瘤中也存在过度表达的现象，而抑制PI3K不仅会影响BCR信号通路，还会对炎症、细胞信号传导和血管生成产生抑制，从而影响与肿瘤增殖有关的微环境。由ICOS与吉利德共同开发的艾代拉利司（idelalisib，商品名：Zydelig）是第一代口服PI3K-delta抑制剂。它于2014年获FDA批准上市治疗复发/难治性慢淋。它临床活性显著，可诱导细胞凋亡、抑制恶性B细胞系/原发肿瘤细胞系增殖，还能阻断多种信号通路，降低肿瘤细胞的生存能力。由Infinity Pharmaceuticals和Verastem共同开发的度恩西布（duvelisib，商品名：Copiktra）则是一款口服PI3K-delta和PI3K-gamma双重抑制剂。它于2018年获FDA批准用于治疗此前至少使用两种其它疗法的成人复发/难治性慢淋。其对PI3K-delta的抑制导致恶性肿瘤细胞凋亡，而对PI3K-gamma的抑制则减少了肿瘤微环境中支持细胞的分化和转移。 B细胞淋巴瘤因子-2（BCL-2）也是一个重要靶点。BCL-2可阻止细胞凋亡，并在某些类型癌症中过度表达，与耐药性的形成相关。比如由艾伯维与罗氏旗下基因泰克共同开发的维奈克拉（venetoclax，商品名：Venclexta），就是一种口服、选择性BCL-2抑制剂，通过选择性抑制BCL-2的功能，恢复细胞的通讯系统，让癌细胞自我毁灭，达到治疗肿瘤的目的。2016~2019年，维奈克拉先后获FDA批准了多项慢淋相关适应症。今年还有一款在中国获批慢淋适应症的BCL-2抑制剂——由亚盛医药研发的利沙托克拉。探索仍在继续过去25年间，美国FDA共批准了至少14款治疗慢淋的新疗法，除上述药物之外，还有2008年获批的化疗药物苯达莫司汀（bendamustine，商品名Treanda），以及2024年获批的靶向CD19的CAR-T细胞疗法lisocabtagene maraleucel（liso-cel，商品名Breyanzi）。药明康德很高兴能为其中多款疗法提供赋能、助力合作伙伴的这些创新疗法来到全球患者身边。为更好地提高慢淋患者的生活质量、解决药物长期使用带来的耐药等问题，产业圈仍在携手努力。当下还有近200款针对慢淋的新疗法正处于积极的临床研究中，有望在未来造福更多患者。其中多款药物已进入3期临床阶段，涵盖小分子靶向药和靶向蛋白降解剂等多种类型。比如由默沙东与ArQule共同研发的nemtabrutinib，近期研究证实其对BTK抑制剂耐药（包括携带BTK C481S突变）的复发或难治性慢淋患者有效，且在TP53异常亚组中仍有疗效，安全性可控。目前科学家正在进行一项3期试验，以评估这款新药对比维奈克拉+利妥昔单抗联合疗法的疗效。在抗击慢淋的漫漫旅途中，这些令人兴奋的成就源于科学家敢于挑战传统的洞见和勇气，也离不开转化医学中来自学术界和产业界的携手努力。最后，让我们再次向那些在慢淋治疗领域不懈探索的英雄们致以崇高的敬意。药明康德也期待与业界同仁继续同行，助力让更多创新疗法来到患者身边。参考资料： [1] Ponader, S., & Burger, J. A. (2014). Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. Journal of clinical oncology, 32(17), 1830-1839. https://doi.org/10.1200/JCO.2013.53.1046 [2] The Wild Story Behind A Promising Experimental Cancer Drug. Retrieved Aug 27, 2025, from https://www.forbes.com/sites/davidshaywitz/2013/04/05/the-wild-story-behind-a-promising-experimental-cancer-drug/ [3] 打造一“键”封喉的共价抗癌药——专访北大深圳研究生院潘峥婴博士. Retrieved Aug 27, 2025, from https://www.wuximediaglobal.com [4] Pharmacyclics. Retrieved Aug 27, 2025 from https://www.pharmacyclics.com/home/who-we-are/history [5] Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., ... & O'Brien, S. (2013). Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 369(1), 32-42. DOI: 10.1056/NEJMoa1215637 [6] Johnson & Johnson, Pharmacyclics, Inc. Breakthrough Drug Wins FDA Approval. Retrieved Aug 27, 2025, from https://www.biospace.com/article/releases/johnson-and-johnson-pharmacyclics-inc-breakthrough-drug-wins-fda-approval-/ [7] The drug that may make chemo a thing of the past. Retrieved Aug 27, 2025, from https://www.mdanderson.org/publications/conquest/spring-2014/the-drug-that-may-make-chemo-a-thing-of-the-past.html [8] New Drug Application (NDA): 205552. Retrieved Aug 27, 2025 from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205552 [9] 西安杨森. Retrieved Aug 27, 2025 from https://www.xian-janssen.com.cn/ [10]上海合全药业2018年度报告. Retrieved Aug 27, 2025 from http://pdf.dfcfw.com/pdf/H2_AN201903221308711829_1.pdf [11] AbbVie Completes Acquisition of Pharmacyclics. Retrieved Aug 27, 2025 from https://investors.abbvie.com/news-releases/news-release-details/abbvie-completes-acquisition-pharmacyclics [12] Ozcan, M., Lavie, D., Chaudhry, A., Zhou, X., Paydar, I., Farooqui, M. Z., & Ghia, P. (2024). BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS7089 [13] Thomas, X. (2013). First contributors in the history of leukemia. World Journal of Hematology, 2(3), 62-70. doi: 10.5315 / wjh.v2.i3.62 [14] Mehranfar, S., Zeinali, S., Hosseini, R., Akbarzadeh, A., Mohammadian, M., & Feizi, A. H. P. (2017). History of leukemia: diagnosis and treatment from beginning to now. Galen Medical Journal, 6(1), e702-e702. DOI: https://doi.org/10.31661/gmj.v6i1.702 [15] Innovation of CLL Treatments: Chemotherapy Era - HealthTree for Chronic Lymphocytic Leukemia. Retrieved Aug 27, 2025 from https://healthtree.org/cll/community/articles/innovation-cll-treatment-chemotherapy-era [16] Rai, K. R., & Jain, P. (2016). C hronic lymphocytic leukemia (CLL)—Then and now. American journal of hematology, 91(3), 330-340. https://doi.org/10.1002/ajh.24282 [17] Perez-Carretero, C., Gonzalez-Gascon-y-Marin, I., Rodriguez-Vicente, A. E., Quijada-Alamo, M., Hernandez-Rivas, J. A., Hernandez-Sanchez, M., & Hernandez-Rivas, J. M. (2021). The evolving landscape of chronic lymphocytic leukemia on diagnosis, prognosis and treatment. Diagnostics, 11(5), 853. doi: 10.3390/diagnostics11050853 [18] 慢性淋巴细胞白血病/小淋巴细胞淋巴瘤诊疗指南（2022年版）. Retrieved Aug 27, 2025 from https://www.nhc.gov.cn/yzygj/c100068/202204/0c1f7d3aca0545abbeb02030ce255930/files/1732863055385_61833.pdf [19] Troubled Infinity licenses cancer drug to Verastem | BioPharma Dive）. Retrieved Aug 27, 2025 from https://www.biopharmadive.com/news/Infinity-duvelisib-verastem-license/429724/ [20] 中国抗癌协会血液肿瘤专业委员会,中华医学会血液学分会,中国慢性淋巴细胞白血病工作组,(2025). 中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的诊断与治疗指南（2025年版）. 中华血液学杂志,46(02)：105-112.DOI:10.3760/cma.j.cn121090-20241209-00551 [21]IMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) . Retrieved Aug 27, 2025 from https://www.prnewswire.com/news-releases/imbruvica-ibrutinib-pooled-outcomes-data-from-three-phase-3-studies-suggest-potential-clinical-efficacy-in-patients-with-high-risk-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-cllsll-300457242.html [22]de Claro, R. A., McGinn, K. M., Verdun, N., Lee, S. L., Chiu, H. J., Saber, H., ... & Pazdur, R. (2015). FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clinical Cancer Research, 21(16), 3586-3590. [23] Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., ... & O'Brien, S. (2015). Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood, The Journal of the American Society of Hematology, 125(16), 2497-2506. https://doi.org/10.1182/blood-2014-10-606038 [24] Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K., ... & O'Brien, S. (2020). Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. Clinical Cancer Research, 26(15), 3918-3927. https://doi.org/10.1158/1078-0432.CCR-19-2856 [25] IMBRUVICA® (ibrutinib) Approved by U.S. FDA for the First-line Treatment of Chronic Lymphocytic Leukemia. Retrieved Aug 27, 2025 from https://news.abbvie.com/2016-03-04-IMBRUVICA-ibrutinib-Approved-by-U-S-FDA-for-the-First-line-Treatment-of-Chronic-Lymphocytic-Leukemia [26] The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | PNAS. Retrieved Aug 27, 2025 from https://www.pnas.org/doi/10.1073/pnas.1004594107 [27] Byrd, J. C., Blum, K. A., Burger, J. A., Coutre, S. E., Sharman, J. P., Furman, R. R., ... & O'Brien, S. M. (2011). Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. Journal of Clinical Oncology, 29(15_suppl), 6508-6508. [28] Phase Ib/II Study of the Activity and Tolerability of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 in CLL/SLL | Research To Practice. Retrieved Aug 27, 2025 from https://www.researchtopractice.com/index.php?q=5MJCASCO2011/CLL/1 [29] Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc. (prnewswire.com) . Retrieved Aug 27, 2025 from https://www.prnewswire.com/news-releases/pharmacyclics-forms-pact-to-develop-and-commercialize-pci-32765-for-hematologic-cancers-with-janssen-biotech-inc-135271818.html [30] Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., ... & Fowler, N. H. (2012). Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Journal of Clinical Oncology, 31(1), 88-94. doi: 10.1200/JCO.2012.42.7906 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床研究

100 项与奥妥珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09321	奥妥珠单抗	L01XC15	DB08935

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
CD20阳性B细胞慢性淋巴细胞白血病	日本	Chugai Pharmaceutical Co., Ltd.	2022-12-23
CD20阳性滤泡性淋巴瘤	日本	Nippon Shinyaku Co., Ltd.	2018-07-02
CD20阳性滤泡性淋巴瘤	日本	Chugai Pharmaceutical Co., Ltd.	2018-07-02
滤泡性淋巴瘤	澳大利亚	F. Hoffmann-La Roche Ltd.	2014-05-15
慢性淋巴细胞白血病	美国	Genentech, Inc.	2013-11-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
狼疮性肾炎	申请上市	美国	Roche Holding AG	2025-03-05
边缘区B细胞淋巴瘤	申请上市	中国	F. Hoffmann-La Roche Ltd.	2019-09-28
肿瘤溶解综合征	临床3期	美国	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	澳大利亚	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	法国	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	希腊	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	塞尔维亚	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	西班牙	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	中国台湾	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	英国	AbbVie, Inc.	2024-08-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02871219 (Phase 2 Study of Obinutuzumab Combined with Lenalidomide, Pubmed \| Blood Adv)	临床2期	滤泡性淋巴瘤一线	90	Obinutuzumab + Lenalidomide	觸鏇繭鑰築鹹鹽鬱簾鏇(蓋艱構築鏇醖餘簾蓋衊) = 繭顧壓構襯鏇淵觸範鏇夢襯蓋壓鑰鹹鏇憲廠糧 (範壓築築窪鹽壓艱醖遞, 88.2 ~ 98.6) 更多	积极	2025-09-09
NCT03580928 (AMPLIFY \| AVO, CTgov)	临床2期	慢性淋巴细胞白血病	72	Acalabrutinib+Venetoclax+Obinutuzumab (Acalabrutinib/Venetoclax/Obinutuzumab (AVO) With Non-high-risk CLL Disease)	夢顧蓋範醖顧築鏇構鹹 = 醖窪艱範憲願獵顧鑰鑰願醖衊壓艱襯窪選範選 (齋積憲鬱觸網廠鑰構衊, 簾觸糧繭餘構繭艱齋簾 ~ 糧繭遞鏇壓繭鹹繭膚衊) 更多	-	2025-08-12
NCT03580928 (AMPLIFY \| AVO, CTgov)	临床2期	慢性淋巴细胞白血病	72	Acalabrutinib+Venetoclax+Obinutuzumab (Acalabrutinib/Venetoclax/Obinutuzumab (AVO) With High-risk CLL Disease)	夢顧蓋範醖顧築鏇構鹹 = 獵網鏇壓鑰鹹積製選蓋願醖衊壓艱襯窪選範選 (齋積憲鬱觸網廠鑰構衊, 齋鬱窪網簾衊糧廠齋範 ~ 鏇鹽範餘衊鹽鏇鑰艱憲) 更多	-	2025-08-12
NCT03872180 (CTgov)	临床2期	套细胞淋巴瘤	23	bendamustine+Venetoclax+Obinutuzumab	積簾鹽淵蓋淵壓憲衊壓 = 廠衊夢襯艱窪簾鏇積獵窪鏇鹹選鬱鬱網鑰鹹齋 (範獵網窪艱簾膚顧衊獵, 簾艱積衊壓醖顧顧觸齋 ~ 觸鏇壓範淵築壓淵艱醖) 更多	-	2025-08-06
NCT01995669 (CTgov)	临床1/2期	复发性边缘区淋巴瘤 \| 难治性滤泡性淋巴瘤 \| 难治性边缘区淋巴瘤 ... 更多	66	Obinutuzimab+Lenolidomide (All Participants)	繭獵鹹選鬱顧齋壓製齋 = 醖廠餘鑰製製淵餘鑰夢蓋築觸壓醖膚鏇膚觸窪 (餘蓋顧糧顧齋蓋築艱壓, 淵襯艱鹹鹹範憲憲鬱餘 ~ 繭蓋憲網鑰構淵網餘獵)	-	2025-06-24
NCT01995669 (CTgov)	临床1/2期	复发性边缘区淋巴瘤 \| 难治性滤泡性淋巴瘤 \| 难治性边缘区淋巴瘤 ... 更多	66	Obin (Ph. II: Expansion Len 20 mg Plus Obin 1000 mg)	夢積簾構築淵繭醖製鏇(積鹽齋積構夢構憲築觸) = 糧鏇構餘鹹範鏇遞願鏇鹹淵範齋選積廠鑰淵選 (醖選繭網築蓋繭鬱製膚, 夢衊網選願積鏇簾鏇繭 ~ 選築憲製餘築獵廠網鬱) 更多	-	2025-06-24
NCT02871219 (Phase 2 Study of Obinutuzumab Combined with Lenalidomide, CTgov)	临床2期	体重下降 \| 疲劳 \| 复发性 3a 级滤泡性淋巴瘤 ... 更多	96	lenalidomide+obinutuzumab	獵觸鬱顧獵遞範鬱顧觸(鹽築鑰壓壓簾餘醖簾憲) = 襯積鏇淵願憲鹽築壓廠糧簾夢衊鏇鹽齋遞築願 (鹹糧鹹鏇鬱糧鬱艱選淵, 艱壓構簾鏇繭壓觸製壓 ~ 鑰憲蓋鏇網蓋窪夢構積) 更多	-	2025-06-08
EHA2025 人工标引	临床阶段不明	复发性滤泡性淋巴瘤	46	Lenalidomide + Obinutuzumab	廠獵積齋鹽壓選遞願糧(簾鹽觸築築鏇廠顧繭壓) = 糧鑰積觸鏇範淵構襯築顧構積壓膚鑰選選顧襯 (構夢願鹽選鹽鑰鹹鏇憲 ) 更多	积极	2025-05-14
EHA2025 人工标引	临床阶段不明	复发性滤泡性淋巴瘤	46	Lenalidomide + Obinutuzumab (patients with CR)	積範艱願壓醖顧鬱齋簾(觸壓獵夢鹽鬱淵鬱網壓) = 憲積淵廠餘鬱願窪範獵構淵選網廠壓鑰鏇範簾 (觸衊夢願願鑰鹹艱襯築 ) 更多	积极	2025-05-14
EHA2025 人工标引	临床阶段不明	滤泡性淋巴瘤一线	233	Obinutuzumab + chemotherapy (G-chemo)	願觸鹽夢鏇獵夢繭蓋範(鹽蓋選襯糧製餘積積憲) = 蓋網餘願衊選鹹獵夢廠壓壓餘簾鏇艱廠網繭糧 (夢淵憲蓋壓醖遞範獵築 ) 更多	积极	2025-05-14
NCT03322865 (OLYMP-1, EHA2025) 人工标引	临床2期	边缘区B细胞淋巴瘤	56	Obinutuzumab	築製觸鑰醖艱齋糧蓋窪(積醖夢鏇鏇憲壓獵獵鹽) = 淵築鹹遞淵衊膚構鹽積願糧壓夢製鏇鹽蓋積蓋 (醖繭齋鹹鏇製襯願願獵 ) 更多	积极	2025-05-14
NCT05823701 (PF953, EHA2025)	临床2期	弥漫性大B细胞淋巴瘤	26	CAGM regimen	觸積廠製餘壓餘觸壓簾(壓廠廠鏇襯醖製衊艱餘) = 鏇鹽醖糧積襯觸願廠膚醖衊鹹憲醖鹹鹽壓窪網 (繭餘簾網築壓糧積鑰膚 ) 更多	积极	2025-05-14
PS1572 (EHA2025)	N/A	慢性淋巴细胞白血病一线	695	Venetoclax-Obinutuzumab	鹽簾遞餘鹹顧簾構鑰範(襯壓餘壓願窪廠壓夢獵) = Persistence remained higher for the Venetoclax-Obinutuzumab cohort vs Acalabrutinib/Zanubrutinib through the expected 1L fixed treatment duration 餘積夢範鹽簾製構簾積 (鹽鑰繭餘窪蓋繭衊願鹹 )	积极	2025-05-14
PS1572 (EHA2025)	N/A	慢性淋巴细胞白血病一线	695	Acalabrutinib		积极	2025-05-14